Hepatitis, Cancer Claims Among Those Subject To FDA "Courtesy" Letters

This article was originally published in The Tan Sheet

07 Jun 1999
News

The Tan Sheet

Executive Summary

Claims to prevent or treat hepatitis and cancer are among statements targeted by FDA in recent "courtesy" letters sent to dietary supplement manufacturers. Washington, D.C.-based Chinese Herb Center received a letter citing claims for Liverin including "It is to be used for chronic hepatitis B, C, D, E and F." Claims for another product, Cervilin, for "cervical syndrome such as cervical bone proliferation and degeneration," also were named in the May 5 letter (see box, p. 9).

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
Consumer
Subjects
OTC Drugs

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer OTC Drugs

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS089900

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS089900

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Hepatitis, Cancer Claims Among Those Subject To FDA "Courtesy" Letters

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert